MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Ir.iderapharma.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Ir.iderapharma.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Ir.iderapharma.com most likely does not offer any adult content.
Popular pages
-
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides
The Investor Relations website contains information about Aceragen, Inc.'s business for stockholders, potential investors, and financial analysts.
-
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
$20.6 million or $0.59 per basic and diluted share for the same period in 2020. Excluding the non-cash loss of approximately $13.1 million for the three months ended September 30, 2020 related to t...
-
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
$8.0 million, or $125.8 million and March 31, 2021 and 2020, respectively, related to the securities issued in connection with the December 2019 private placement transaction, net loss applicable t...
-
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the...
-
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic
Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Ider...
-
Press Releases | Investor Relations | Aceragen, Inc.
You are leaving investors.aceragen.com, a website provided [on behalf of /by] Aceragen.